Myrcludex B: Completed Ph IIb MYR 202 enrollment

Hepatera and MYR completed enrollment of 120 patients in the open-label, Russian and German Phase IIb MYR 202 trial to evaluate Myrcludex B with Viread tenofovir for 24 weeks. Hepatera in-licensed rig...